DNA damaging agents including anthracyclines, camptothecins and platinum drugs are among most frequently used drugs in the chemotherapeutic routine. Due to their relatively low selectivity for cancer cells, administration is associated with adverse side effects, whereas the inherent genotoxicity of these drugs is associated with risk of developing secondary cancers. Development of new drugs, which could be spared of these drawbacks and at the same would characterize with improved antitumor efficacy, remains challenging yet vitally important task. These properties are in large part dictated by the selectivity of interaction between the drug and DNA and in this way the studies aimed at elucidating the complex interactions between ligand and DNA represent a key step in the drug development. Studies of the drug-DNA interactions encompass determination of DNA sequence specificity and mode of DNA binding as well as kinetic, dynamic and structural parameters of binding. Here, we consider the types of interactions between small molecule ligands and polynucleotides, how they are affected by DNA sequence and structure and what is their significance for the antitumor activity. Based on this knowledge we discuss the wide array of experimental techniques available to researchers for studying drug-DNA interactions, which include absorption and emission spectroscopies, NMR, magnetic and optical tweezers or atomic force microscopy. We show, using the clinical and experimental anticancer drugs as examples, how these methods provide various types of information and at the same time complement each other to provide full picture of drug-DNA interaction and aid in the development of new drugs

Misiak, M., Mantegazza, F., Beretta, G. (2016). Methods for Elucidation of DNA-Anticancer Drug Interactions and their Applications in the Development of New Drugs. CURRENT PHARMACEUTICAL DESIGN, 22(44), 6596-6611 [10.2174/1381612822666160831114622].

Methods for Elucidation of DNA-Anticancer Drug Interactions and their Applications in the Development of New Drugs

MANTEGAZZA, FRANCESCO
Secondo
;
2016

Abstract

DNA damaging agents including anthracyclines, camptothecins and platinum drugs are among most frequently used drugs in the chemotherapeutic routine. Due to their relatively low selectivity for cancer cells, administration is associated with adverse side effects, whereas the inherent genotoxicity of these drugs is associated with risk of developing secondary cancers. Development of new drugs, which could be spared of these drawbacks and at the same would characterize with improved antitumor efficacy, remains challenging yet vitally important task. These properties are in large part dictated by the selectivity of interaction between the drug and DNA and in this way the studies aimed at elucidating the complex interactions between ligand and DNA represent a key step in the drug development. Studies of the drug-DNA interactions encompass determination of DNA sequence specificity and mode of DNA binding as well as kinetic, dynamic and structural parameters of binding. Here, we consider the types of interactions between small molecule ligands and polynucleotides, how they are affected by DNA sequence and structure and what is their significance for the antitumor activity. Based on this knowledge we discuss the wide array of experimental techniques available to researchers for studying drug-DNA interactions, which include absorption and emission spectroscopies, NMR, magnetic and optical tweezers or atomic force microscopy. We show, using the clinical and experimental anticancer drugs as examples, how these methods provide various types of information and at the same time complement each other to provide full picture of drug-DNA interaction and aid in the development of new drugs
Articolo in rivista - Review Essay
Anticancer Drug, Atomic Force Microscopy, Circular Dichroism, DNA, Fluorescence, Magnetic Tweezers, Nuclear Magnetic Resonance
English
6596
6611
16
Misiak, M., Mantegazza, F., Beretta, G. (2016). Methods for Elucidation of DNA-Anticancer Drug Interactions and their Applications in the Development of New Drugs. CURRENT PHARMACEUTICAL DESIGN, 22(44), 6596-6611 [10.2174/1381612822666160831114622].
Misiak, M; Mantegazza, F; Beretta, G
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/135616
Citazioni
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 13
Social impact